Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

DNA2.0 Partnering With Aldevron

By Drug Discovery Trends Editor | September 5, 2012

DNA2.0, a leading bioengineering solutions provider, announced a partnership with Aldevron to improve recombinant protein production in insect cell culture. By pairing DNA2.0‘s GeneGPS technology with Aldevron’s protein production experience, the two companies will develop enhanced gene synthesis algorithms for baculovirus protein expression in insect cells.

“Aldevron’s expertise in protein expression and production compliments DNA2.0’s gene design and expression optimization technology,” said Tom Foti, Vice President of Aldevron. “Through this collaboration, we will be able to provide our clients an improved method for producing high quality proteins with increased yields—all while saving them crucial time and money.”

Insect cell expression systems are valued for high expression levels that permit folding, oligomerization and other post-translational modifications in manners that are often identical to those that occur in mammalian cells. By increasing the productivity from insect cell culture, the collaboration between Aldevron and DNA2.0 will further benefit drug discovery research and commercial therapeutic protein production.

“We have successfully optimized expression for a variety of hosts, including bacteria, yeast, fungus, plant, and mammalian, and we are excited to team with Aldevron to extend our expertise to baculovirus expression in insect cells,” said Jeremy Minshull, PhD, cofounder and CEO of DNA2.0. “By combining our patented GeneGPS technology—which has been proven to increase protein expression up to 100-fold—with Aldevron’s strength in large scale protein production, I’m confident that we will develop a best-in-class solution for insect cell culture.”

Date: August 30, 2012
Source: DNA2.0


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE